TTY Biopharm Valuation
Is 4105 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 4105 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 4105 (NT$79.9) wird unter unserer Schätzung des Fair Value (NT$80.01) gehandelt.
Deutlich unter dem Marktwert: 4105 unter dem beizulegenden Zeitwert gehandelt wird, jedoch nicht um einen signifikanten Betrag.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4105?
Other financial metrics that can be useful for relative valuation.
What is 4105's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NT$19.49b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.5x |
Enterprise Value/EBITDA | 12.2x |
PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does 4105's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 56.7x | ||
1789 ScinoPharm Taiwan | 76.4x | n/a | NT$21.9b |
4746 Formosa Laboratories | 111x | n/a | NT$14.0b |
4114 Synmosa Biopharma | 25.4x | n/a | NT$15.1b |
1720 Standard Chemical & Pharmaceutical | 14.1x | n/a | NT$11.7b |
4105 TTY Biopharm | 17.3x | 18.7% | NT$19.5b |
Price-To-Earnings gegen Gleichaltrige: 4105 ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (17.2x) mit dem Durchschnitt der anderen Unternehmen (43.3x) vergleicht.
Price to Earnings Ratio vs Industry
How does 4105's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: 4105 ist aufgrund seines Price-To-Earnings Verhältnisses (17.2x) im Vergleich zum TW Pharmaceuticals Branchendurchschnitt (24x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is 4105's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 17.3x |
Fair PE Ratio | 16.2x |
PM vs. Fair Ratio: 4105 ist teuer auf der Grundlage des Verhältnisses Price-To-Earnings (17.2x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (16.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | NT$78.40 | NT$86.50 +10.3% | 9.8% | NT$95.00 | NT$78.00 | n/a | 2 |
Mar ’25 | NT$80.80 | NT$86.50 +7.1% | 9.8% | NT$95.00 | NT$78.00 | n/a | 2 |
Feb ’25 | NT$78.40 | NT$86.50 +10.3% | 9.8% | NT$95.00 | NT$78.00 | n/a | 2 |
Jan ’25 | NT$80.40 | NT$86.00 +7.0% | 10.5% | NT$95.00 | NT$77.00 | n/a | 2 |
Dec ’24 | NT$83.10 | NT$86.00 +3.5% | 10.5% | NT$95.00 | NT$77.00 | n/a | 2 |
Nov ’24 | NT$84.50 | NT$86.00 +1.8% | 10.5% | NT$95.00 | NT$77.00 | n/a | 2 |
Sep ’24 | NT$76.60 | NT$85.00 +11.0% | 9.4% | NT$93.00 | NT$77.00 | n/a | 2 |
Aug ’24 | NT$76.40 | NT$85.00 +11.3% | 9.4% | NT$93.00 | NT$77.00 | n/a | 2 |
Jul ’24 | NT$78.40 | NT$84.50 +7.8% | 10.1% | NT$93.00 | NT$76.00 | n/a | 2 |
Jun ’24 | NT$75.00 | NT$78.00 +4.0% | 2.6% | NT$80.00 | NT$76.00 | n/a | 2 |
May ’24 | NT$76.90 | NT$78.00 +1.4% | 2.6% | NT$80.00 | NT$76.00 | n/a | 2 |
Apr ’24 | NT$76.20 | NT$74.00 -2.9% | 8.1% | NT$80.00 | NT$68.00 | NT$78.40 | 2 |
Mar ’24 | NT$77.90 | NT$71.50 -8.2% | 4.9% | NT$75.00 | NT$68.00 | NT$80.80 | 2 |
Feb ’24 | NT$77.40 | NT$71.50 -7.6% | 4.9% | NT$75.00 | NT$68.00 | NT$78.40 | 2 |
Jan ’24 | NT$83.40 | NT$79.50 -4.7% | 5.7% | NT$84.00 | NT$75.00 | NT$80.40 | 2 |
Dec ’23 | NT$78.50 | NT$79.50 +1.3% | 5.7% | NT$84.00 | NT$75.00 | NT$83.10 | 2 |
Nov ’23 | NT$74.90 | NT$76.50 +2.1% | 2.0% | NT$78.00 | NT$75.00 | NT$84.50 | 2 |
Oct ’23 | NT$72.70 | NT$76.50 +5.2% | 2.0% | NT$78.00 | NT$75.00 | NT$77.20 | 2 |
Sep ’23 | NT$75.20 | NT$73.00 -2.9% | 6.8% | NT$78.00 | NT$68.00 | NT$76.60 | 2 |
Aug ’23 | NT$70.90 | NT$73.00 +3.0% | 6.8% | NT$78.00 | NT$68.00 | NT$76.40 | 2 |
Jul ’23 | NT$71.10 | NT$73.00 +2.7% | 9.6% | NT$85.00 | NT$68.00 | NT$78.40 | 4 |
Jun ’23 | NT$69.00 | NT$73.00 +5.8% | 9.6% | NT$85.00 | NT$68.00 | NT$75.00 | 4 |
May ’23 | NT$74.70 | NT$73.00 -2.3% | 9.6% | NT$85.00 | NT$68.00 | NT$76.90 | 4 |
Apr ’23 | NT$69.00 | NT$73.00 +5.8% | 9.6% | NT$85.00 | NT$68.00 | NT$76.20 | 4 |
Analysten-Prognose: Das Kursziel liegt weniger als 20% über dem aktuellen Aktienkurs.